<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00577590</url>
  </required_header>
  <id_info>
    <org_study_id>487</org_study_id>
    <nct_id>NCT00577590</nct_id>
  </id_info>
  <brief_title>Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM</brief_title>
  <acronym>T2DM</acronym>
  <official_title>Cyclotron Produced Isotopes in Biology and Medicine, Project 3: Specific Aim 1A and 1B Effects of Fatty Acid Delivery on Myocardial Metabolism and Function in Type 2 Diabetes (T2DM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 Diabetes Mellitus (T2DM) is a disease that interferes with the body's proper
      production and use of insulin, a hormone needed to convert sugar into usable energy. People
      with Type 2 Diabetes Mellitus (T2DM) are at a higher risk for certain cardiovascular
      diseases, including heart disease and stroke. Normal treatments for Type 2 Diabetes Mellitus
      (T2DM) target blood sugar levels only, but there is reason to believe that also targeting
      blood fat levels will improve both sugar metabolism and heart function in people with Type 2
      Diabetes Mellitus, (T2DM.) This study will determine the effectiveness of blood-fat lowering
      treatments along with blood-sugar control treatments in improving heart function and symptoms
      of people with Type 2 Diabetes Mellitus(T2DM), and if this varies between men and women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 Diabetes Mellitus, (T2DM) is the most common type of diabetes. In Type 2 Diabetes
      Mellitus (T2DM), the body does not properly process sugars and, as a result, there is an
      excess amount of sugar in the blood. Eventually, the high blood sugar levels can lead to
      heart disease, nerve damage, kidney problems, or blindness. Typical Type 2 Diabetes Mellitus
      (T2DM) treatments target maintenance of blood sugar levels. Previous studies on Type 2
      Diabetes Mellitus (T2DM) have indicated that in people who have high amounts of fats in the
      blood, the body relies more heavily on fats than sugars as an energy source. This dependence
      on fats for energy has been shown to have a negative effect on heart function. There is
      reason to believe that lowering the levels of fats in the blood will enhance the ability of
      the heart and the whole body to efficiently use both fats and sugars as energy sources. This
      study will evaluate the effectiveness of treatment strategies that are designed to reach
      target levels of sugar and fat in the blood for treating people with Type 2 Diabetes Mellitus
      (T2DM).

      Participation in this double-blind study will last between 4 and 6 months. First,
      participants will undergo a medical screening and medication adjustment period, expected to
      last 6 months. The medical screening, lasting about 1 hour, will involve completing a medical
      history, physical exam, pregnancy test if applicable, and blood test to measure various
      factors that contribute to diabetes control. Participants will also be asked permission to
      store 1 tablespoon of their blood for up to 10 years to be used in future studies concerning
      genetics and heart energy metabolism. During the medication adjustment period, study
      physicians will adjust the participants' medications, offer advice on diabetes education and
      nutrition, and record any side effects from the medications. For newly diagnosed Type 2
      Diabetes Mellitus (T2DM) participants, the study physician may recommend medication changes
      to assure a hemoglobin A1c (HgA1c) level of less than 7.5%. If participants have already
      achieved this level, they will be asked to continue present medications and to also begin
      taking the medication metformin for the 30 days before they undergo several imaging studies.
      Next, participants will complete routine tests that evaluate the pumping function of the
      heart, including an electrocardiogram (ECG) performed before and during exercise, a body
      composition study using a dual energy x-ray absorptiometry (DEXA) scan, and a magnetic
      resonance imaging (MRI) test. Each of these tests will last between 30 and 90 minutes.

      After the qualifying tests, participants will return for the first of two separate imaging
      days that will include the same tests. The second imaging day will occur at the end of the
      medication period, approximately 2 months after the first imaging day. The first tests will
      be a whole body metabolism study and a heart metabolism imaging study, performed
      simultaneously. The whole body metabolism study will involve the injection of two tracers of
      metabolism, one for glucose and one for fatty acids. The heart metabolism imaging study will
      involve a positron-emission tomographic (PET) scan to take pictures of the heart and will
      include blood draws. The final imaging test will be a resting echocardiogram (ECHO) to
      measure heart function.

      Following completion of the first day of imaging tests, participants will be randomly
      assigned to one of three possible treatment groups: Group A ,B, or C. Group A will take
      Metformin alone.Group B will take Metformin and Rosiglitazone. Group C will take Metformin
      and Lovaza. Participants will be seen monthly for the next 4 months, during which study
      medication will be distributed and blood pressure, heart rate, weight, and any side effects,
      such as lower extremity swelling, will be measured. If there is a noticeable increase in
      swelling, study physicians may adjust medication dosages. During visits at Months 2 and 4,
      blood samples will be taken to measure liver and organ function and HgA1c. At the completion
      of the 4-month medication treatment, participants will undergo repeat imaging tests. If
      needed, participants will be offered the opportunity to attend one or more follow-up visits
      to re-establish a medication routine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Plasma Triglycerides</measure>
    <time_frame>Baseline and 3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>Metformin Alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants assigned to take Metformin alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin and Rosiglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to take Metformin and Rosiglitazone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin and Lovaza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to take Metformin and Lovaza</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin is taken alone</description>
    <arm_group_label>Metformin Alone</arm_group_label>
    <arm_group_label>Metformin and Lovaza</arm_group_label>
    <arm_group_label>Metformin and Rosiglitazone</arm_group_label>
    <other_name>Glumetza, Glucophage, Fortamet, Riomet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>Rosiglitizone is taken with Metformin</description>
    <arm_group_label>Metformin and Rosiglitazone</arm_group_label>
    <other_name>Advandia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovaza</intervention_name>
    <description>Lovaza is taken with Metformin</description>
    <arm_group_label>Metformin and Lovaza</arm_group_label>
    <other_name>Omega-3 acid ethyl esters</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets Americans with Disabilities Act (ADA) criteria for T2DM; if newly diagnosed,
             must have fasting blood glucose greater than 126 mg/dl on two occasions, a random
             blood glucose greater than 200 mg/dl with symptoms, or a diagnostic oral glucose
             tolerance test

          -  Weight of less than 350 pounds

          -  Hemoglobin A1c of equal to or less than 7.5% at study entry or willing to go on one of
             the following therapies to achieve necessary percentage: metformin monotherapy greater
             than 1000 mg daily for at least 30 days or metformin greater than 1000 mg daily plus
             any combination of sulfonylurea, glipizide, or alpha-glucosidase inhibitor

          -  Blood pressure less than 140/90 mm Hg at study entry

          -  LDL level less than 130 mg/dL if on stable lipid lowering regimen

          -  Willing to undergo normal rest/stress (treadmill or dobutamine) echocardiogram

          -  If currently taking thyroid replacement therapy, must be on a stable dose of thyroid
             replacement and must have a thyroid function blood test that is in the normal range

          -  Willing to use an effective form of birth control throughout the study

        Exclusion Criteria:

          -  Received therapy with an insulin sensitizer of the thiazolidinedione class within 6
             months prior to study entry

          -  Required insulin therapy for more than 2 weeks in the year prior to study entry

          -  History of angina, heart attack, coronary artery bypass grafting (CABG), stroke,
             congestive heart failure (CHF), or peripheral vascular disease (PVD)

          -  Known coronary artery disease (CAD) with residual lesions of greater than 50%

          -  Current smoker

          -  Use or expected use of corticosteroids in any form

          -  Serum triglycerides greater than 400 mg/dl on a fasting sample at study entry

          -  Any contraindication to a thiazolidinedione (TZD) insulin sensitizer, metformin, or
             other drugs likely to be used during the study

          -  Liver disease with liver function test (LFT) greater than 2 times the upper limit of
             normal (ULN)

          -  Serum creatinine greater than 1.5 mg/dl for women and 1.6 mg/dl for men OR greater
             than 2+ proteinuria on urine dipstick
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Gropler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998 Apr;21(4):518-24.</citation>
    <PMID>9571335</PMID>
  </reference>
  <reference>
    <citation>Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, Mitch W, Smith SC Jr, Sowers JR. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1999 Sep 7;100(10):1134-46. Review. Erratum in: Circulation 2000 Apr 4;101(13):1629-31.</citation>
    <PMID>10477542</PMID>
  </reference>
  <reference>
    <citation>Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol. 1974 Jul;34(1):29-34.</citation>
    <PMID>4835750</PMID>
  </reference>
  <reference>
    <citation>Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care. 1992 Jul;15(7):820-5.</citation>
    <PMID>1516498</PMID>
  </reference>
  <reference>
    <citation>Abbott RD, Donahue RP, Kannel WB, Wilson PW. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham Study. JAMA. 1988 Dec 16;260(23):3456-60. Erratum in: JAMA 1989 Apr 7;261(13):1884.</citation>
    <PMID>2974889</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 18, 2007</study_first_submitted>
  <study_first_submitted_qc>December 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2007</study_first_posted>
  <results_first_submitted>February 9, 2018</results_first_submitted>
  <results_first_submitted_qc>August 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2018</results_first_posted>
  <last_update_submitted>August 24, 2018</last_update_submitted>
  <last_update_submitted_qc>August 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type II Diabetes Mellitus</keyword>
  <keyword>Diabetes</keyword>
  <keyword>PET</keyword>
  <keyword>Heart Metabolism</keyword>
  <keyword>Lovaza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Metformin and Lovaza</title>
          <description>Participants assigned to take metformin and Lovaza
Lovaza: Dosage of 4 g to be taken daily for 2 months
Metformin: Dosage of at least 1000 mg to be taken daily for 4 months</description>
        </group>
        <group group_id="P2">
          <title>Metformin</title>
          <description>Participants assigned to take metformin and placebo
Metformin: Dosage of at least 1000 mg to be taken daily for 4 months</description>
        </group>
        <group group_id="P3">
          <title>Metformin and Rosiglitazone</title>
          <description>Patients received Metformin and Rosiglitizone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin and Lovaza</title>
          <description>Participants assigned to take metformin and Lovaza
Lovaza: Dosage of 4 g to be taken daily for 2 months
Metformin: Dosage of at least 1000 mg to be taken daily for 4 months</description>
        </group>
        <group group_id="B2">
          <title>Metformin</title>
          <description>Participants assigned to take metformin and placebo
Metformin: Dosage of at least 1000 mg to be taken daily for 4 months</description>
        </group>
        <group group_id="B3">
          <title>Metformin and Rosiglitizone</title>
          <description>Participants assigned to take Metformin and Rosiglitizone</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="27"/>
                    <count group_id="B3" value="23"/>
                    <count group_id="B4" value="78"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Plasma Triglycerides</title>
        <time_frame>Baseline and 3 months</time_frame>
        <population>Data presented are stratified by sex</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin and Lovaza</title>
            <description>Participants assigned to take metformin and Lovaza
Lovaza: Dosage of 4 g to be taken daily for 2 months
Metformin: Dosage of at least 1000 mg to be taken daily for 4 months</description>
          </group>
          <group group_id="O2">
            <title>Metformin</title>
            <description>Participants assigned to take metformin and placebo
Metformin: Dosage of at least 1000 mg to be taken daily for 4 months</description>
          </group>
          <group group_id="O3">
            <title>Metformin and Rosiglitazone</title>
            <description>Patients received Metformin and Rosiglitizone</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Plasma Triglycerides</title>
          <population>Data presented are stratified by sex</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Plasma triglycerides women</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="12"/>
                    <measurement group_id="O2" value="16.0" spread="30"/>
                    <measurement group_id="O3" value="-5.0" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma triglycerides men</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="12"/>
                    <measurement group_id="O2" value="-10.0" spread="5"/>
                    <measurement group_id="O3" value="1.0" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Metformin and Lovaza</title>
          <description>Participants assigned to take metformin and Lovaza
Lovaza: Dosage of 4 g to be taken daily for 2 months
Metformin: Dosage of at least 1000 mg to be taken daily for 4 months</description>
        </group>
        <group group_id="E2">
          <title>Metformin</title>
          <description>Participants assigned to take metformin and placebo
Metformin: Dosage of at least 1000 mg to be taken daily for 4 months</description>
        </group>
        <group group_id="E3">
          <title>Metformin and Rosiglitizone</title>
          <description>Participants assigned to take Metformin and Rosiglitizone</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations or caveats</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Robert Gropler, MD, Chief of Cardiovascular Imaging Laboratory</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-747-3877</phone>
      <email>groplerr@mir.wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

